A carefully-designed protocol for this GLP-1 RA double-blind randomised-controlled primary prevention trial should address the ultimate goal of exploring its effect on nondiabetic and non-CVD population in preventing cardiovascular disease, chronic kidney disease, obesity, dyslipidaemia, hypertension, NAFLD, PCOS, and perioperative complications of bariatric surgery. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.